Subcutaneous ICD Noninferior to Transvenous ICD
WEDNESDAY, Aug. 5, 2020 -- For patients with an indication for an implantable cardioverter defibrillator (ICD) but no indication for pacing, subcutaneous ICD is noninferior to transvenous ICD, according to a study published in the Aug. 6 issue of the New England Journal of Medicine.
Reinoud E. Knops, M.D., Ph.D., from the University of Amsterdam, and colleagues conducted a noninferiority trial involving patients with an indication for an ICD but not for pacing who were randomly assigned to receive either a subcutaneous ICD or transvenous ICD (426 and 423 patients, respectively). The composite of device-related complications and inappropriate shocks was examined as the primary end point.
The researchers found that a primary end point event occurred in 68 patients in the subcutaneous ICD group and 68 in the transvenous ICD group at a median follow-up of 49.1 months (48-month Kaplan-Meier estimated cumulative incidence, 15.1 and 15.7 percent, respectively; hazard ratio, 0.99; 95 percent confidence interval, 0.71 to 1.39; P = 0.01 for noninferiority; P = 0.95 for superiority). Device-related complications occurred in 31 and 44 patients in the subcutaneous and transvenous ICD groups, respectively (hazard ratio, 0.69; 95 percent confidence interval, 0.44 to 1.09); inappropriate shocks occurred in 41 and 29 patients, respectively (hazard ratio, 1.43; 95 percent confidence interval, 0.89 to 2.30).
"The trial provides data to aid patients and providers in their shared decision making regarding ICD selection," write the authors of an accompanying editorial.
Several authors disclosed ties to pharmaceutical companies, including Boston Scientific, which supported the study.
© 2020 HealthDay. All rights reserved.
Posted: August 2020
Read this next
MONDAY, Sept. 28, 2020 -- Intrauterine exposure to maternal gestational diabetes is associated with increased cardiovascular disease risk and risk factors in offspring up to age...
MONDAY, Sept. 28, 2020 -- Metabolic surgery on patients with morbid obesity and pharmacologically treated hypertension is associated with lower risk for major adverse...
MONDAY, Sept. 28, 2020 -- Having two or more moderate or severe menopausal symptoms (MS) is associated with an increased risk for stroke and cardiovascular disease (CVD),...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.